Introduction {#Sec1}
============

Nowadays, a variety of probiotics have been explored and applied to food and therapeutic interests, of which lactic acid bacteria biologics are the dominant types due to their biological functions and safety. Among the enteric commensal *Escherichia* species, *E. coli* Nissle 1917 (*Ec*N) is the only one which has been authorized as a probiotic and applied to treat various human gastrointestinal disorders and infections, including diarrhea, diverticulitis, and inflammatory bowel disease (IBD) (Secher et al. [@CR47]; Sonnenborn [@CR51]). Furthermore, as a safe delivery vector, *Ec*N has been successfully developed to upload various functional allergens in the allergy desensitization, wherein its probiotic functions have been extended synergistically due to the immunotherapy line (Sarate et al. [@CR46]). In a colorectal cancer chemoprevention test, the recombinant *Ec*N was directed specifically to the cancer cell surface and in situ expressed myrosinase to perform the host-ingested glucosinolate hydrolysis for sulphoraphane production (Ho et al. [@CR21]). Besides, genetically engineered *Ec*N strains have been used in vaccine and pharmaceutical preparations (Chaudhari et al. [@CR7]; Ou et al. [@CR37]). When the *Ec*N is employed for probiotic therapy, the viability of *Ec*N is one important factor that determines the final therapeutic effect, therefore, to sustain the survival of *Ec*N on a desired level is necessary during probiotic therapy.

It is rational that forming biofilm and persister cells will promote population colonizing onto the gastrointestinal tract mucosal layer, thereby allowing probiotics to in situ develop and carry out functional therapies. Previous studies showed that biofilm formation promotes the ability of *Lactobacillus* strains in resistance to temperature, gastric pH and mechanical forces (Salas-Jara et al. [@CR45]), and a bile-induced biofilm formation during stationary growth allows *Bifidobacteria* strains for strong colonization in the gastrointestinal tract (Ambalam et al. [@CR1]). It is evident that the probiotic mechanism of *Ec*N is inseparable from its colonization ability (Hancock et al. [@CR18]). Beyond the contribution of pili (F1A, F1C, and curly fimbriae), iron chelating carriers, and uptake systems, the better capacity of *Ec*N in biofilm formation competitively inhibits adhesion and invasion of pathogenic *E. coli* to intestinal epithelial cells (Dembinski et al. [@CR10]; Jiang et al. [@CR23]). Persister cells firstly reported in the early 1940s are phenotypic variants in a given population that presents antibiotic tolerance due to their slow or non-growing state (Page and Peti [@CR38]). Persister cells are able to revert to normal growth when the adverse stimuli such as antibiotics are removed. As studies progressed, forming persister cells has been generally accepted as an important strategy for bacteria to survive upon hostile environments (Page and Peti [@CR38]; Van den Bergh et al. [@CR56]). Moreover, the persistence phenomenon has been widely described and determined in *E. coli*. Therefore, it is likely that cells in a persistent state will be helpful for *Ec*N to become the winner during outcompeting with the pathogenic enteric microbiome in the intestine. However, the current understanding of the underlying mechanisms involved in the biofilm and persister formation of *Ec*N is inadequate.

Multiple signaling layers have been reported to participate in modulating biofilm and persister formation, including stringent control (Fujita et al. [@CR13]), quorum sensing system (Li et al. [@CR30]), c-di-GMP signaling pathway (Moreira et al. [@CR35]), and toxin-antitoxin system (TAS) (Sun et al. [@CR52]). Among these, TAS has attracted much attention due to their critical roles in cell physiologies such as programmable cell death, biofilm formation, and persister formation (Harms et al. [@CR19]; Page and Peti [@CR38]). A typical TAS constituted a bicistron line which is composed of a stable toxin or growth arrest factor and its unstable inhibitor (antitoxin) (Yang and Walsh [@CR62]). Currently, six types of TASs have been classified, wherein the distribution and prevalence of type II are the most dominant and universal in bacteria and *Archaea* (Page and Peti [@CR38]). In *E. coli*, more than ten kinds of type II TASs have been studied, of which the F-plasmid-based *ccdAB* and high persistence allele *hipAB* are two of the best characterized and identified that are mainly responsible for the plasmid maintenance and persister formation, respectively (Ogura and Hiraga [@CR36]; Semanjski et al. [@CR48]; Wen et al. [@CR60]). However, the relevant knowledge in *Ec*N is still insufficient. In addition to their critical roles in physiologies, TASs have recently been developed as an efficient counterselectable marker in *E. coli* recombineering. For example, the toxic gene *ccdB* is developed as a counterselection module to improve seamless mutagenesis and the efficiency of high-throughput, restriction-free cloning, and screening process in *E. coli* (Wang et al. [@CR58]; Lund et al. [@CR32]). Endogenous TAS *ydcE*-*ydcD* has been used for constructing a stable and food-grade expression system in *Bacillus subtilis* (Yang et al. [@CR63]). These shed light on the application of endogenous TASs in the genetic modification of *Ec*N in terms of plasmid construction and chromosomal gene knock-in.

In the current study, we identified two type II TAS pairs and investigated their physiological roles in *Ec*N. To achieve this, the well-known gene-editing tool CRISPR interference (CRISPRi) is first introduced to annotate TAS. We demonstrated that the identified *ccdAB* and *hipAB* are associated with the formation of biofilm and persister cells in *Ec*N. Our findings highlight that TASs may be an important candidate in the in situ engineering of *Ec*N when employed as probiotic therapy to sustain cell viability, and CRISPRi will be an efficient and robust tool in driving the engineering process.

Materials and methods {#Sec2}
=====================

Bacterial strains, plasmids, and growth conditions {#Sec3}
--------------------------------------------------

The strains and plasmids used in this study were listed in Table [1](#Tab1){ref-type="table"}. All strains were grown in LB medium (10 g/L peptone, 5 g/L yeast extract, 10 g/L NaCl) at 37 °C, with shaking at 180 r/min (liquid culture). For plasmid maintenance, LB medium was supplemented with ampicillin (50 μg/mL), kanamycin (50 μg/mL), and chloramphenicol (25 μg/mL) when appropriate. *E. coli* DH5α and BL21 (DE3) were applied for plasmid propagation and preparation, and protein expression, respectively.Table 1Strains and plasmids used in this studyStrains/plasmidsCharacteristics or descriptions^a^SourceStrains  *Ec*N*Escherichia coli* Nissle 1917, wildtypeKind gift from Zheyi hospital  *E. coli* K-12 *substr*. MG1655Wildtype and plasmid freeLab storage  *Ec*N Δ*ccdAB*Knockdown expression of *ccdAB* by CRISPRi systemThis study  *Ec*N Δ*hipAB*Knockdown expression of *hipAB* by CRISPRi system.This study  *Ec*N Δ*hipAB*Δ*ccdAB*Knockdown expression of *hipAB* and *ccdAB* by CRISPRi systemThis study  *E. coli* DH5αDH5α strain was used for cloning and plasmid maintenanceTaKaRa  *E. coli* BL21(DE3)BL21 (DE3) strain was used for recombinant protein expressionNovagen  *E. coli*::pECA*Escherichia coli* BL21 (DE3) carrying plasmid pECA (Amp^R^)This study  *E. coli*::pECB*Escherichia coli* BL21 (DE3) carrying plasmid pECB (Amp^R^)This study  *E. coli*::pECAB*Escherichia coli* BL21 (DE3) carrying plasmid pECAB (Amp^R^)This study  *E. coli*::pETDuet-1*Escherichia coli* BL21 (DE3) carrying plasmid pETDuet-1 (Amp^R^)This study  *E. coli*::pEHA*Escherichia coli* BL21 (DE3) carrying plasmid pEHA (Amp^R^)This study  *E. coli*::pEHB*Escherichia coli* BL21 (DE3) carrying plasmid pEHB (Amp^R^)This study  *E. coli*::pEHAB*Escherichia coli* BL21 (DE3) carrying plasmid pEHAB (Amp^R^)This study  *Ec*N::pdCas9::pgRCB*Escherichia coli* Nissle 1917 carrying plasmid pdCas9-bacteria and pgRCB (Amp^R^ and Cm^R^)This study  *Ec*N::pdCas9::pgRHB*Escherichia coli* Nissle 1917 carrying plasmid pdCas9-bacteria and pgRHB (Amp^R^ and Cm^R^)This study  *Ec*N::pdCas9::pURCBH*Escherichia coli* Nissle 1917 carrying plasmid pdCas9-bacteria and pURCBH (Amp^R^ and Cm^R^)This studyPlasmids  pETDUet-1*E. coli* expression vector. Ampicillin resistance. This vector is designed for the co-expression of two target genes. The vector contains two multiple cloning sites (MCS1 and MCS2), each of which is preceded by a T7 promoter/lac operator and a ribosome binding site. ColE1 repliconNovagen  pgRNA-bacteriaPlasmid used for gRNA biosynthesis (Amp^R^)Addgene  pdCas9-bacteriaPlasmid used for the expression of dCas9 (Cm^R^)Addgene  pECBPlasmid used for the expression of *ECOLIN_00245* (Amp^R^)This study  pECAPlasmid used for the expression of *ECOLIN_00240* (Amp^R^)This study  pECABPlasmid used for the expression of *ECOLIN_00240* and *ECOLIN_00245* (Amp^R^)This study  pEHBPlasmid used for the expression of *ECOLIN_08370* (Amp^R^)This study  pEHAPlasmid used for the expression of *ECOLIN_08365* (Amp^R^)This study  pEHABPlasmid used for the expression of *ECOLIN_08370* and *ECOLIN_08365* (Amp^R^)This study  pgRCBPlasmid used for the biosynthesis of sgRNA involved in *ccdAB* knockdown analysis (Amp^R^)This study  pgRHBPlasmid used for the biosynthesis of sgRNA involved in *hipAB* knockdown analysis (Amp^R^)This study  pURCBHPlasmid used for the biosynthesis of sgRNA involved in *hipAB* and *ccdAB* knockdown analysis (Km^R^)This study^a^*Cm*^*R*^, chloramphenicol resistance; *Amp*^*R*^, ampicillin resistance; *Km*^*R*^, kanamycin resistance

Bioinformatics analysis {#Sec4}
-----------------------

Putative type II TASs in the *E. coli* genome were predicted by a web-based tool TA finder (<http://202.120.12.133/TAfinder/index.php>) using default parameters. Comparative analysis of the TASs in *Ec*N with other *E. coli* species was performed using the BLAST tool involved in NCBI (<https://www.ncbi.nlm.nih.gov/>). The synteny analysis of TASs in each *E. coli* strains was carried out by SyntTax (<http://archaea.u-psud.fr/SyntTax/>). BPROM was used for the prediction of putative promoters (<http://www.softberry.com/>). The homologous sequences of ECOLIN_00240, ECOLIN_00245, ECOLIN_08365, and ECOLIN_08370 from other *E. coli* groups were used for the construction of phylogenetic trees via MEGA6.0 software (Tamura et al. [@CR53]). The evolutionary history was determined using the neighbor-joining method and the *p*-distance method. The phylogeny test was evaluated by bootstrap analysis (1000 replicates). All positions containing gaps and missing data were deleted. The conserved domain of ECOLIN_00240, ECOLIN_00245, ECOLIN_08365, and ECOLIN_08370 was analyzed by CDD, a web-based tool (<https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?>).

Cloning and expression of putative toxin and antitoxin genes {#Sec5}
------------------------------------------------------------

Putative toxin and antitoxin genes were amplified by PCR using the *Ec*N genome as the template and Prime STAR Max DNA Polymerase (TaKaRa, Japan), with the primers listed in Table [S1](#MOESM1){ref-type="media"} (P1-P8, supplementary materials). The obtained DNA fragments were inserted into the multiple cloning sites MCS1 and MCS2 included in pETDuet-1 (Novagen) after double digestion by appropriate restriction enzymes (*Bam*HI and *Pst*I for gene encoding toxin, and *Kpn*I and *Eco*RV for gene encoding antitoxin), respectively, to produce plasmid comprising gene encoding either toxin or antitoxin protein or both. Positive colonies were selected by colony-PCR using primer P9-P12 (Table [S1](#MOESM1){ref-type="media"}) and verified by sequencing. Evaluation of the toxicity of toxin proteins was performed as previously described with some modifications (Xia et al. [@CR61]). Shortly, overnight cultures of *E. coli* BL21 (DE3) comprising different plasmids were inoculated to fresh LB medium with 1% inoculum and grown until an OD~600~ of 0.25 ± 0.05. Then, 1 mM IPTG was added and cell growth was monitored by measuring OD~600~ of the cultures. After induction for 4 h, the aliquots of each culture were 10-fold serially diluted and spotted on plates without IPTG to detect cell viability. All primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.

Construction of CRISPRi system and knockdown expression of *ccdAB* and *hipAB* {#Sec6}
------------------------------------------------------------------------------

In CRISPRi system, the nuclease-deficient Cas9 (dCas9) was expressed using an anhydrotetracycline (aTc) inducible promoter, while the single-guide RNA (sgRNA) was expressed continuously with promoter J23119 (Qi et al. [@CR39]). In order to inhibit the expression of *ccdAB* and *hipAB* in vivo, two specifically designed sgRNAs comprising 20-nucleotide (nt) spacer sequence (N20 sequence) complementary to the target genes *ccdB* and *hipB* were designed by a web-based tool (<http://crispr.dbcls.jp/>), respectively. To improve the efficiency, six N20 sequences possessing the best hits were selected and synthesized in the form of primers (three for each gene) (Table [S1](#MOESM1){ref-type="media"}, sequence underlined, only one best N20 sequence was shown). The detailed processes of construction were shown in supplementary materials (Fig. [S1](#MOESM1){ref-type="media"}a). Briefly, DNA fragments containing the N20 sequence were amplified by PCR using plasmid pgRNA-bacteria as the template. The obtained DNA fragments were purified and sub-cloned into plasmid pgRNA-bacteria between *Spe*I and *Bam*HI restriction sites to produce plasmid pgRCB and pgRHB. The positive colonies were verified by sequencing. The plasmid pgRCB and pgRHB were transformed into *Ec*N along with pdCas9-bacteria to create the respective *ccdAB* and *hipAB* knocked-down strains (Fig. [S1](#MOESM1){ref-type="media"}b). To repress the expression of *ccdAB* and *hipAB*, 2 μM aTc (Sigma, USA) was added to the culture medium at the indicated time. The repression of gene expression was confirmed by RT-PCR. To suppress the transcription of *ccdAB* and *hipAB* simultaneously, the plasmid pURCBH comprising the sgRNA targeting to *ccdB* and *hipB* was constructed and transformed along with pdCas9-bacteria into *Ec*N (Fig. [S2](#MOESM1){ref-type="media"}).

RNA extraction, RT-PCR, and qRT-PCR analysis {#Sec7}
--------------------------------------------

Overnight cultures of *Ec*N::pdCas9::pgRCB, *Ec*N::pdCas9::pgRHB~**,**~ and *Ec*N::pdCas9::pURCBH were inoculated to fresh LB medium with 1% inoculum (2 μM aTc was added to the medium where indicated) and grown until OD~600~ of 0.6 ± 0.05, respectively. Cell samples were collected by centrifugation (8000 r/min, 5 min). RNA extraction was carried out using TaKaRa MiniBEST Universal RNA Extraction Kit (TaKaRa, Japan) according to the manufacturer's instructions. The RNA yield and quality were evaluated with a NanoDrop UV spectrometer (Thermo Scientific, USA). The first-strand cDNA was synthesized using the PrimeScript™II 1st Strand cDNA Synthesis Kit (TaKaRa, Japan). The purified cDNA fragments were used as the template in the following polymerase chain reaction (PCR) analysis. For quantitative reverse transcription (qRT-PCR) analysis, the RNA samples were prepared similarly. Shortly, overnight cultures of *EcN*, *Ec*N::pdCas9::pgRCB, *Ec*N::pdCas9::pgRHB, and *Ec*N::pdCas9::pURCBH were inoculated to fresh LB medium containing 2 μM aTc with 1% inoculum and grown for 24 h. Then, cells were collected by centrifugation and used for RNA extraction and cDNA synthesis as described above. The qRT-PCR was performed with the SYBR *Premix Ex Taq*™II Kit (TaKaRa) with a final volume of 20 μL, which contained 10 μL of SYBR Premix Ex Taq II, 0.4 μL of each primer (final concentration 0.4 μM), 2 μL of cDNA, and 7.2 μL of RNase-free dH~2~O. All of the primers used in this part were listed in Table [S1](#MOESM1){ref-type="media"} (P23-P42). The amplification procedure included denaturation at 95 °C for 5 min; 40 cycles of 95 °C for 15 s, and 60 °C for 30 s. The melting curves were analyzed by Taipu TIB8600 qRT-PCR system (Taipu, China). The data were analyzed by the ΔΔCt method using 16S rRNA as an internal reference. The relative fold change was calculated from 2^−ΔΔCt^, in which, ΔCt = Ct target gene -- Ct internal reference gene, ΔΔCt = Ct sample -- Ct control.

Biofilm formation assay {#Sec8}
-----------------------

The assay of biofilm formation was performed as previously reported with some modifications (Sun et al. [@CR52]). In brief, 50 μL aliquots of each culture were inoculated into 5 mL fresh LB medium (with or without aTc) contained in two different 6-well polystyrene culture plates (final OD~600~ of \~ 0.05), followed by incubating at 37 °C without shaking for 24 h. Then, the medium was discarded, and the wells were gently rinsed with 1X PBS to remove planktonic and loosely adhered cells. The adhered biofilm was quantified by staining the cells with 1% crystal violet solution for 30 min at room temperature. The excess crystal violet was removed by washing the wells three times with distilled water. Crystal violet bound to the adhered cells was solubilized in 1 mL of 95% ethanol and quantified by measuring absorbance at 540 nm and 620 nm. For biofilm assay using a differential interference microscope (Olympus U-LH100-3, Japan), the sterilized coverslips were added to the well after inoculation as described above. After incubation for 24 h, the coverslips were taken out and washed gently using PBS buffer (0.15 M, pH 7.2) to remove the planktonic cells. The biofilm formation of each tested group was captured using the microscope. All experiments were performed with three independent biological replicates.

Persistence assay {#Sec9}
-----------------

All antibiotics (USP grade) were purchased from Sangon Biotech (Shanghai) Co., Ltd. The minimal inhibitory concentration (MIC) of gentamycin and norfloxacin was detected as previously reported (Andrews [@CR2]). Briefly, overnight cultures of different strains were diluted by 1:100 into fresh LB medium containing gentamycin or norfloxacin with different concentrations. The mixtures were added to 96-well plates (200 μL in each well) and incubated at 37 °C for 24 h. The optical density (OD~600~) was determined by a microtiter plate reader (Victor™X3, PerkinElmer). The lowest antibiotic concentration that inhibited visible bacterial growth was defined as the MIC (OD change \< 0.05). For persistence level detection, a time-dependent killing curve was assayed. In brief, overnight cultures of different strains were inoculated into fresh LB medium with or without aTc (2 μM) and grown for 24 h, followed by adding gentamycin or norfloxacin to a final concentration of 10-fold the MIC. Following treatment, cells collected at indicated time by centrifugation (8000 r/min, 3 min) were washed and re-suspended using a fresh LB medium. The suspension was then serially diluted and plated on LB agar plates to obtain the colony-forming units (CFU/mL). Persistence shown as survival (%) was obtained by dividing the number of surviving cells following treatment with antibiotics by the total number of cells without treatment.

Statistical analysis {#Sec10}
--------------------

All statistical analyses were performed using Origin software (version 9.0). Where appropriate, the data were analyzed using Student's *t* test. Differences were considered statistically significant at *p* \< 0.05. Values in the figure were expressed as the mean of three biological replicates ± one standard deviation.

Results {#Sec11}
=======

Two loci are identified as functional TASs belonging to *ccdAB* and *hipAB* {#Sec12}
---------------------------------------------------------------------------

Putative type II TASs in *the Ec*N chromosome were predicted using a web-based tool TA finder. Totally, 16 TASs were found (Fig. [1a](#Fig1){ref-type="fig"}), which was higher than the average level of TASs distribution observed in other *E. coli* species (\~ 10) (Fiedoruk et al. [@CR12]). Among them, most of the TA modules possessed toxins belonging to RelE and YhaV super-families and antitoxins belonging to HTH_XRE and PrlF super-families, respectively. We chose two of them for further functional analysis in the current study. *ECOLIN_00240* (52351...52584) and *ECOLIN_00245* (52587...52901), encoding two proteins of 77 aa and 104 aa, were predicted as a typical TAS *ccdAB*. The genetic structure analysis showed that they formed the canonical bicistronic structure of the toxin-antitoxin system, with the antitoxin gene *ECOLIN_00240* locating upstream of the toxin gene *ECOLIN_00245* with 2 bases in distance (Fig. [1b](#Fig1){ref-type="fig"}). These two genes shared a promoter upstream of the *ECOLIN_00240*, which was predicted by BPROM. Additionally, conserved domain analysis of these two proteins showed that ECOLIN_00245 and ECOLIN_00240 possessed the domain belonging to CcdB (pfam01845) and CcdA (COG5302), respectively, suggesting that they might be a functional TAS. Similarly, *ECOLIN_08365* (1709929...1711248) and *ECOLIN_08370* (1711248...1711514) were suggested to constitute a functional TAS belonging to *hipAB* based on genetic structure and conserved domain analysis. For example, *ECOLIN_08370* located upstream of *ECOLIN_08365* with one base (A) overlapped, and both of them shared a promoter (Fig. [1c](#Fig1){ref-type="fig"}). ECOLIN_08370 (88 aa) and ECOLIN_08365 (439 aa) possessed the domain included in HipB (PRK09726) and HipA (cd17808), respectively.Fig. 1Characterization of type II toxin-antitoxin systems in *Ec*N. **a** Map distribution of putative type II toxin-antitoxin systems in the *Ec*N chromosome. Text in red and black indicates the toxin part and the antitoxin part, respectively. **b** Chromosomal synteny analysis of *ECOLIN_00240* (*ccdA*) and *ECOLIN_00245* (*ccdB*). **c** Chromosomal synteny analysis of *ECOLIN_08370* (*hipB*) and *ECOLIN_08365* (*hipA*). White arrows represent hypothetical proteins. **d** Growth curves of *E. coli* BL21 (DE3) derivatives carrying plasmid pECA, pECB, pECAB, and pETDUet-1. **e** Cell growth on LB plate after induction for 4 h. **f** Growth curves of *E. coli* BL21 (DE3) derivatives carrying plasmid pEHA, pEHB, pEHAB, and pETDUet-1. **g** Cell growth on LB plate after induction for 4 h. Mean values and standard deviations (error bars) are shown from the three biological replicates. Red arrows indicate the addition of IPTG

To investigate the activity of individual toxins, the *E. coli* was used for host killing assay. Expression of CcdB induced by IPTG significantly inhibited cell growth and viability as shown by a decrease in turbidity and colony-forming units (CFU/mL) (Fig. [1](#Fig1){ref-type="fig"} d and e). In contrast, the expression of CcdA did not affect cell growth and colony-forming activity. Besides, the toxic effect of CcdB could be neutralized by co-expressing with CcdA. Likewise, toxin HipA overexpressed robustly caused cell growth arrest, and this inhibition could be abolished when HipA was co-expressed with antitoxin HipB (Fig. [1f](#Fig1){ref-type="fig"}). Moreover, toxin HipA remarkably reduced the colony-forming activity of *E. coli* cells (Fig. [1g](#Fig1){ref-type="fig"}). These observations were consistent with previous reports wherein overexpression of HipA and CcdB resulted in dramatic growth slowdown (Germain et al. [@CR15]; Gupta et al. [@CR17]). Combined, these results suggested that the *ECOLIN_00240*-*ECOLIN_00245* and *ECOLIN_08365*-*ECOLIN_08370* of *Ec*N constituted the typical TAS *ccdAB* and *hipAB*, respectively.

In addition to the canonical HipAB described above, a tricomponent *hipAAB* was also observed in the *Ec*N chromosome (Fig. [1a](#Fig1){ref-type="fig"}). Interestingly, the *hipA* was split into two genes *hipA*~N~ (4900381...4900968, encoding N terminus domain) and *hipA*~C~ (4901039...4901650, encoding C terminus domain). Recently, a novel family of tricomponent TAS consisted of *hipS*, *hipT*, and *hipB* was identified in *E. coli* wherein the *hipS* and *hipT* exhibited sequence similarity to N terminus and C terminus of *hipA*, respectively (Vang Nielsen et al. [@CR57]). We further compared the sequence of *hipA*~N~ and *hipA*~C~ with that of *hipS* and *hipT* and found a low similarity between *hipA*~N~ and *hipS*, as well as *hipA*~C~ and *hipT* (data not shown). These suggested that the split *hipA* and *hipB* might form a novel tricomponent TA system in *Ec*N, which needs future investigation.

*Ec*N shares similar genetic structure of CcdAB and HipAB with pathogenic *E. coli* species {#Sec13}
-------------------------------------------------------------------------------------------

The amino acid sequences of CcdB, CcdA, HipA, and HipB from *Ec*N were used as the reference sequences to search the homologs in other *E. coli* strains whose genome had been sequenced, including the well-known commensal *Escherichia coli* (CMEC) as well as the pathogenic groups such as enterohemorrhagic *E. coli* (EHEC), enteropathogenic *E. coli* (EPEC), and enterotoxigenic *E. coli* (ETEC) (Chaudhuri and Henderson [@CR8]). Totally, 79 complete genome sequences were selected (Table [S2](#MOESM1){ref-type="media"}). We found that CcdA was highly conserved in strains belonging to group EPEC, ExPEC, EHEC, and APEC since most of them had the homologs that were tightly clustered together with *Ec*N (Fig. [2a](#Fig2){ref-type="fig"}). Sequence alignment of CcdA showed that there was no or only one mutation (S76R) in most of the strains belonging to these four groups while abundant mutations were found in ETEC and CMEC group strains (Fig. [S3](#MOESM1){ref-type="media"}). Similarly, the CcdB was also conserved in pathogenic groups where only two mutations were observed (G10S and E28V) but largely absent in group CMEC (Fig. [2b](#Fig2){ref-type="fig"} and [S4](#MOESM1){ref-type="media"}). The influence of these mutations on the binding efficiency of CcdAB to DNA gyrase needs future investigation. In addition to the sequence conservation between *Ec*N and pathogenic *E. coli* groups, the highly conserved flanking genes adjacent to *ccdAB* operon were also observed, whereas 80% of the selected CMEC strains lost the complete *ccdAB* systems (Fig. [2c](#Fig2){ref-type="fig"}). The loss of *ccdAB* in CMEC might result from the toxin loss during the evolutionary process as usually observed in previous studies (Martins et al. [@CR33]; Ramisetty and Santhosh [@CR41]). Taken together, these findings suggested that CcdAB might function similarly in *Ec*N and pathogenic *E. coli* strains.Fig. 2Comparative and phylogenetic analysis of CcdAB among different *E. coli* serotypes. Phylogenetic tree of CcdA (**a**) and CcdB (**b**). The numbers in the bracket such as "4/5" indicate that 4 out of 5 strains in EPEC have the CcdA homologs. **c** Schematic representation of the flanking genes adjacent to CcdAB. EHEC, enterohemorrhagic *E. coli*; EPEC, enteric pathogenic *E. coli*; ETEC, enterotoxigenic *E. coli*; ExPEC, extraintestinal pathogenic *E. coli*; APEC, avian pathogenic *E. coli*; CMEC, commensal *E. coli*. The strains used in each group were shown in Table [S2](#MOESM1){ref-type="media"}. The numbers on the left such as "23/35" represent that 23 out of 35 strains in EHEC possess a similar synteny structure. Arrows with the same color represent the homologous sequences, and white arrows indicate hypothetical proteins. 1, glutathione-regulated potassium-efflux system protein KefF; 2, glutathione-regulated potassium-efflux system protein KefC; 3, type 3 dihydrofolate reductase; 4, bis(5′-nucleosyl)-tetraphosphatase (symmetrical); 5, Co2+/Mg2+ efflux protein ApaG; 6, ribosomal RNA small subunit methyltransferase A; 7, 4-hydroxythreonine-4-phosphate dehydrogenase; 8, chaperone SurA

In comparison to CcdAB, the well-known HipAB was overall less conserved in different *E. coli* groups (Fig. [3](#Fig3){ref-type="fig"}). For one thing, few homologs were obtained by BLAST analysis using the *Ec*N HipA and HipB as the reference (Fig. [3a and b](#Fig3){ref-type="fig"}). For example, only 8 of the 35 EHEC strains had HipA, which resulted from the loss of amino acids (\~ 70 aa) in N terminus (Table [S2](#MOESM1){ref-type="media"}). For another, the surrounding genes of *hipAB* were not conserved in *E. coli* groups since few similar synteny structures were found (Fig. [3c](#Fig3){ref-type="fig"}). On the other hand, HipA or HipB of *Ec*N was closely clustered together with that of ExPEC and APEC strains, which was consistent with the results obtained in CcdAB analysis wherein both CcdA and CcdB were more conserved in pathogenic groups. Moreover, the highly conserved flanking genes adjacent to *hipAB* operon was found in strains belonging to ETEC and ExPEC. Sequence alignment analysis of HipA and HipB presented that the main mutations in HipA homologs were I104L, D107N, V110I, C112R, K234E, Q277R, K290R, K382R, N408T, P435R, R436E, I437Y, R438G, Y439S/I, and the deletion of K in 440; mutations in HipB were T11M, S53T, A73T, A80S, and A81T (Fig. [S5](#MOESM1){ref-type="media"} and [S6](#MOESM1){ref-type="media"}). The influence of these changes on the activity of HipAB deserves future study. Taken together, the CcdAB and HipAB from *Ec*N were more prevalent in strains included in groups other than CMEC, indicating that despite the probiotic nature of *E. coli* Nissle 1917, it belongs to the phylogenetic group B2, occupied mostly by pathogenic strains responsible for extraintestinal infections (ExPEC).Fig. 3Comparative and phylogenetic analysis of HipAB among different *E. coli* serotypes. Phylogenetic tree of HipA (**a**) and HipB (**b**). **c** Schematic representation of the flanking genes adjacent to HipAB. 1, hypothetical protein; 2, trans-aconitate 2-methyltransferase; 3, hypothetical protein; 4, LysR transcriptional regulator; 5, NAD (P)-dependent oxidoreductase; 6, fimbrial protein; 7, fimbrial chaperone protein FimC

CRISPRi-mediated repression of *ccdAB* and *hipAB* {#Sec14}
--------------------------------------------------

To investigate the physiological role of *ccdAB* and *hipAB* in *Ec*N, CRISPRi-mediated gene knockdown analysis was carried out. In order to inhibit the expression of *ccdAB* and *hipAB* operon, the antitoxin part *hipB* and toxin part *ccdB* were selected for the target of dCas9, respectively. The RT-PCR results showed that the expression of *ccdA* was successfully inhibited under the addition of aTc since no visible DNA fragments were amplified using primer P19 and P20 compared with that of the control group (without aTc) (Fig. [4a](#Fig4){ref-type="fig"}, lanes 2 and 4). The expression of *ccdA* was restored after removing the inducer aTc (Fig. [4a](#Fig4){ref-type="fig"}, lane 6), which confirmed that *ccdA* and *ccdB* were in the same operon and shared a promoter. In order to exclude the experimental bias resulted from the addition of aTc, the 16S rDNA was used as the endogenous control. As shown in lane 1, lane 3, and lane 5, DNA fragments of \~ 250 bp were amplified by using primer P17 and P18 upon either aTc was added or not. Therefore, the expression of *ccdAB* operon was successfully repressed by targeting the *ccdB* using CRISPRi. Likewise, transcription of *hipA* was inhibited by targeting *hipB* since no visible DNA fragment was amplified when using primer P21 and P22 (Fig. [4b](#Fig4){ref-type="fig"}, lane 4), whereas in the control group (without aTc or 16S rDNA), a bright DNA band was displayed (Fig. [4b](#Fig4){ref-type="fig"}, lanes 1, 2, 3, and 5). This inhibition could be released by removing aTc (Fig. [4b](#Fig4){ref-type="fig"}, lane 6), indicating that *hipA* and *hipB* were in the same operon and shared a promoter. Collectively, the expression of *ccdAB* and *hipAB* could be repressed by designing sgRNA that targeted either the toxin gene or the antitoxin gene.Fig. 4Transcriptional repression of *ccdAB* and *hipAB* by CRISPRi. Overnight culture of each strain was diluted by 1:100 to 40 mL fresh LB medium supplemented with aTc (2 μM) and grown to exponential phase (OD~600~ = 0.6 ± 0.05). Then, cells were collected and used for RNA extraction. For restored expression of *ccdAB* or/and *hipAB*, aTc was removed by centrifugation and 40 mL fresh LB medium was added to resuspend the cells, following by incubation at 37 °C with shaking for another 4 h. Then, cells were collected and used for RNA and cDNA preparation. **a** Verification of the transcriptional silencing of *ccdAB* by RT-PCR. The cDNA reverse transcribed from RNA prepared from *Ec*N::pdCas9::pgRCB was used as the template. Lanes, 16S rDNA amplification using primer P17 and P18 (lane 1, lane 3, and lane 5); *ccdA* amplification using primer P19 and P20 (lane 2, lane 4, and lane 6); M indicates marker. **b** Verification of the transcriptional silencing of *hipAB* by RT-PCR. The cDNA reverse transcribed from RNA prepared from *Ec*N::pdCas9::pgRHB was used as the template. Lanes, 16S rDNA amplification using primer P17 and P18 (lane 1, lane 3, and lane 5); *hipA* amplification using primer P21 and P22 (lane 2, lane 4, and lane 6). **c** and **d** Verification of the simultaneous transcriptional repression of *ccdAB* and *hipAB*. The cDNA reverse transcribed from RNA prepared from *Ec*N::pdCas9::pURCBH was used as the template. Lanes, 16S rDNA amplification using primer P17 and P18 (lane 1 and lane 4 in **c**, and lane 1 in **d**); *ccdA* amplification using primer P19 and P20 (lane 2 and lane 5 in **c**, and lane 2 in **d**); *hipA* amplification using primer P21 and P22 (lane 3 and lane 6 in **c**, and lane 3 in **d**). "+" and "−" represent the aTc or corresponding primer was added or not, respectively. "+/−" indicates that the aTc was initially added and then removed. All primer sequences were displayed in Table [S1](#MOESM1){ref-type="media"}

Take the multiple and complex functions of TASs into consideration, it is more preferable to investigate several TASs simultaneously. To test if the expression of *hipAB* and *ccdAB* could be interrupted simultaneously, a plasmid pURCBH carrying sgRNA that targeted specifically to *hipB* and *ccdB* was constructed and co-transformed with pdCas9-bacteria. After induction, no visible DNA fragments of \~ 250 bp were amplified when using primer P19 and P20 (Fig. [4c](#Fig4){ref-type="fig"}, lane 5), and P21 and P22 (lane 6), compared with that of the control group (lane 2 and 3), indicating that the transcription of *ccdA* and *hipA* were both repressed. This was further supported by the observation that the expression of *ccdA* and *hipA* were restored upon aTc elimination (Fig. [4d](#Fig4){ref-type="fig"}, lane 2 and 3). Meanwhile, the DNA fragments were always obtained when using the cDNA reverse transcribed from 16S rRNA as the template (Fig. [4c](#Fig4){ref-type="fig"}, lane 1and 4; Fig. [4d](#Fig4){ref-type="fig"}, lane 1). Combined, these results suggested that the expression of *ccdAB* and *hipAB* could be inhibited either separately or simultaneously by the CRISPRi system, and CRISPRi was an efficient tool for parallel annotation of multiple TASs.

Transcriptional silencing of *ccdAB* and *hipAB* leads to the decreased formation of biofilm {#Sec15}
--------------------------------------------------------------------------------------------

The role of CcdAB and HipAB in biofilm formation was studied. Biofilm formation was quantified by the crystal violet assay (Sun et al. [@CR52]). The results showed that the inhibited expression of either *ccdAB* or *hipAB* significantly reduced the biofilm formation of *Ec*N compared with that of control groups (wildtype and non-induced group), with the value of OD~540~/OD~620~ decreased from 1.87 to 1.49, and 1.94 to 1.62, respectively (Fig. [5a](#Fig5){ref-type="fig"}). When the expression of *ccdAB* and *hipAB* were both repressed, the biofilm formation was also sharply decreased with the value dropped from 1.77 to 1.35 (Fig. [5a](#Fig5){ref-type="fig"}). Beyond the crystal violet staining assay, the in situ morphology of biofilm was also captured by a differential interference microscope (Fig. [S7](#MOESM1){ref-type="media"}). Compared with the control in which no biofilm was observed, the wild-type *Ec*N formed thick biofilm after a 24-h incubation (Fig. [S7](#MOESM1){ref-type="media"}a), which was consistent with the previous report that *Ec*N could form biofilm inherently (Chen et al. [@CR9]). The silence of *ccdAB* or/and *hipAB* expression significantly attenuated the biofilm formation and produced an obviously thinned sheet-like biofilm (Fig. [S7](#MOESM1){ref-type="media"}b-d), which supported the results obtained in the crystal violet assay. Collectively, these findings suggested that HipAB and CcdAB functioned actively in the biofilm formation of *Ec*N.Fig. 5Effect of the transcriptional repression of *ccdAB* and *hipAB* on the biofilm (**a**) and persister (**b**) formation of *Ec*N. The values are mean of three biological replicates. Error bars indicate standard deviations. "\*" represents that there is a significant difference between two studied groups (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001)

Knockdown expression of *ccdAB* and *hipAB* reduces persister formation upon gentamycin treatment {#Sec16}
-------------------------------------------------------------------------------------------------

In addition to biofilm formation, the role of CcdAB and HipAB in the persister formation of *Ec*N was investigated. The persister phenomenon had not been described in *Ec*N, thus to evade the experimental bias, a common *E. coli* strain MG1655 was used as the control. Furthermore, considering that the *Ec*N recombinant strains possessed antibiotic resistance to ampicillin and chloramphenicol or kanamycin, the aminoglycosides gentamycin which kills cells by preventing translation via binding to the ribosome 30S subunit was harnessed (Shan et al. [@CR49]). The MIC of gentamycin to *Ec*N, MG1655, and *Ec*N derivatives was 11 μg/mL, 11 μg/mL, and 9 μg/mL, respectively. In the time-dependent killing assay, the stationary phase cells were exposed to 10-fold the MIC of gentamycin over a prolonged time. The CFU/mL of each strain before antibiotic treatment was close (\~ 2 × 10\^9). The results showed that persister cells existed in the stationary phase of *Ec*N, depending on the observations that the bulk of the bacterial population was killed rapidly within 4 h and a subsequent surviving population was kept at a frequency around 0.001% (Fig. [5b](#Fig5){ref-type="fig"}). The persister fraction of *Ec*N was much lower than that observed in *E. coli* MG1655 (\~ 0.1%). The silence of *ccdAB* expression significantly decreased the persister frequency of *Ec*N with 3 log units compared with that in wild-type *Ec*N. Similarly, knockdown expression of *hipAB* also reduced the formation of persister cells with 2 log units. Furthermore, it is noteworthy that when the expression of *ccdAB* and *hipAB* were both repressed, we were unable to isolate viable cells from the culture over the 2-h treatment of gentamycin. Taken together, HipAB and CcdAB were proposed to play an important role in the persister formation of *Ec*N.

Transcriptional interruption of *ccdAB* and *hipAB* affects the expression of genes involved in stress response {#Sec17}
---------------------------------------------------------------------------------------------------------------

To investigate the possible targets that were affected by the inhibited expression of *ccdAB* and *hipAB*, nine genes involved in biological processes like DNA replication (*gyrA*), SOS response (*recA* and *lexA*) (Durfee et al. [@CR11]), stringent response (*rpoS* and *relA*) (Durfee et al. [@CR11]), biofilm formation (*focA*) (Lasaro et al. [@CR29]), TASs (*hipB* and *ccdB*), and post-transcriptional gene regulation (*hfq*) (Henderson et al. [@CR20]) were selected for transcription analysis since these processes were previously reported to be relevant with the stress response of *E. coli*. First, the transcription of *ccdB* and *hipB* were almost blocked when the expression of dCas9 was induced by adding aTc (the relative fold change of mutant strain was lower than 0.15 compared with that in wild-type *Ec*N, Fig. [6a](#Fig6){ref-type="fig"}). Interestingly, the transcription of *hipAB* was significantly inhibited in *Ec*NΔ*ccdAB*, whereas the expression of *ccdAB* was not affected in *Ec*NΔ*hipAB*, indicating that CcdAB might have a positive influence on the expression of HipAB. Second, when the expression of *ccdAB* and *hipAB* were both repressed, the transcription of *gyrA* and *focA* were significantly reduced (Fig. [6a](#Fig6){ref-type="fig"}). DNA and F1C fimbriae are responsible for the biofilm formation of *E. coli* (Lasaro et al. [@CR29]; Zhao et al. [@CR64]); thus, the results obtained here suggested that HipAB and CcdAB mediated the biofilm formation of *Ec*N by positively regulating the expression of *gyrA* and *focA*. Third, knockdown expression of either *ccdAB* or *hipAB* resulted in the remarkably increased expression of *hfq*, *recA*, *rpoS*, and *relA*, with the relative fold change ranging from 2.25- to 3.5-fold compared with that in wild-type *Ec*N. Moreover, the expression of *lexA* was downregulated in Δ*ccdAB* mutant while upregulated in Δ*hipAB* mutant (Fig. [6a](#Fig6){ref-type="fig"}). Combined, these results suggested that SOS response and stringent response mediated by CcdAB and HipAB contributed to the biofilm formation of *Ec*N.Fig. 6Effect of knockdown expression of *ccdAB* and *hipAB* on the transcription of genes involved in different biological processes (**a**). Time-dependent killing kinetics of *Ec*N and *Ec*N mutants treated with 10-fold the MIC of norfloxacin (**b**). *focA*, FIC fimbriae; *relA*, (p)ppGpp synthetase RelA; *rpoS*, response regulator RpoS; *ccdB*, toxin CcdB of TAS CcdAB; *hipB*, toxin HipB of TAS HipAB; *recA*, recombinase RecA; *lexA*, repressor LexA; *hfq*, RNA-binding protein Hfq; *gyrA*, DNA gyrase subunit A. The values are mean of three biological replicates. Error bars indicate standard deviations. The same color in **a** and **b** indicates the same strain. "\*" represents that there is a significant difference between two studied groups (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001)

SOS response is essential in protecting cells from oxidative stress (Bernier et al. [@CR5]; Recacha et al. [@CR43]). Thus, it is rational to speculate that the upregulation of these genes will increase the survival of cells upon treatment with antibiotics that are capable of causing oxidative damage. To test our speculation, norfloxacin, a fluoroquinolone, inhibits DNA replication via affecting the activity of DNA gyrase, was used in the killing assay (Gadebusch and Shungu [@CR14]). The norfloxacin MIC of *Ec*N wildtype and derivatives was 1 μg/mL. As expected, when exposed to norfloxacin, wild-type *Ec*N was sharply killed within 6 h (Fig. [6b](#Fig6){ref-type="fig"}), whereas the reduction of viable cells in *Ec*NΔ*ccdAB*, *Ec*NΔ*hipAB*, and *Ec*NΔ*ccdAB*Δ*hipAB* were relatively slower. Moreover, the eventual survival rate of *Ec*N derivatives was significantly higher than that observed in wild-type *Ec*N (*p* \< 0.05), which indicated that knockdown expression of *ccdAB* and *hipAB* induced SOS response.

Discussion {#Sec18}
==========

Conserved distribution of CcdAB and HipAB shared by the probiotic *Ec*N and pathogenic *E. coli* mediates non-strictly coincident bioprocesses {#Sec19}
----------------------------------------------------------------------------------------------------------------------------------------------

Initially, it was supposed that *Ec*N would contain different TASs from those pathogenic *E. coli*, whereas the contrast results were obtained. Almost, the probiotic *Ec*N and pathogenic *E. coli*, rather than the commensal group, shared the same types and distribution of TASs. Previous studies revealed that the distribution of TASs in *E. coli* is linked with living niches, and the number of TA loci per strain is different among phylogenetic groups (A, B1, B2, and D) (Fiedoruk et al. [@CR12]). Furthermore, horizontal gene transfer is responsible for the TAS evolution of *E. coli* by gene insertion and deletion (Ramisetty and Santhosh [@CR41]). Therefore, the TASs in *Ec*N and other pathogenic strains are suggested to undergo similar evolutionary history, which may result from similar stress stimuli. CcdAB and HipAB are well-known modules involved in plasmid maintenance and bacterial persistence. As the firstly identified and well-studied TAS, plasmid-encoded CcdAB is mainly involved in plasmid maintenance via a process known as postsegregational killing (Ogura and Hiraga [@CR36]). The chromosomal *ccd* operon of *E. coli* O157 is involved in drug tolerance, conferring protection from cell death during exposure to multiple antibiotic stress (Gupta et al. [@CR17]). To our knowledge, the role of CcdAB in biofilm formation is still unclear to date. Our results suggest that CcdAB facilitates the biofilm formation of *Ec*N under given conditions (Fig. [5a](#Fig5){ref-type="fig"}). Accordingly, changes in the transcription level of several genes associated with biofilm formation were observed. The inhibition of *ccdAB* expression induced the upregulated expression of genes involved in the stringent response (*rpoS* and *relA*) (Fig. [6a](#Fig6){ref-type="fig"}), which supported the previous findings in *E. coli* wherein *rpoS* deletion increased the biofilm formation of strain O157:H7 and a *relA* mutant of DS291 had improved ability to build biofilm (Balzer and McLean [@CR4]; Sheldon et al. [@CR50]). Previously, HipA has been restricted to its role in persistence mediation via triggering nutrition starvation through the phosphorylating of glutamyl-tRNA synthetase (GltX), tryptophanyl-tRNA synthetase, and other substrates, whereas its role in biofilm formation is rarely reported (Germain et al. [@CR15]; Semanjski et al. [@CR48]; Vang Nielsen et al. [@CR57]). Zhao and co-workers showed that HipA affects biofilm formation through DNA release (Zhao et al. [@CR64]). Here, transcriptional repression of *hipAB* significantly reduced the expression of *gyrA*, suggesting that one positive role of HipAB in regulating the biofilm formation of *Ec*N is achieved by increasing the DNA synthesis. Knockdown expression of *hipAB* also caused the upregulated expression of genes involved in the stringent response, which further suggests that stringent response may function negatively in the biofilm formation of *Ec*N. Interestingly, the expression of *hfq* and *recA* were upregulated when the transcription of *hipAB* and *ccdAB* were inhibited, contradicting the previous finding that *recA* deletion reduced the biofilm production by 22--80% in *E. coli* when exposed to the sub-MIC of ciprofloxacin (Recacha et al. [@CR43]). Our results suggest that *recA* may act negatively in the biofilm formation of *Ec*N. Thus, how SOS response contributes to the biofilm formation of *Ec*N needs future investigation. RNA chaperone Hfq is a well-known stress response regulator and functions primarily in sRNA-mediated post-transcriptional gene regulation via facilitating the pairing between sRNAs and their target mRNAs (Henderson et al. [@CR20]; Liu et al. [@CR31]). *E. coli* seems less prone to form biofilm upon the deletion of *hfq*, which contradicts our observation here that upregulation of *hfq* expression corresponded to lower biofilm formation (Kulesus et al. [@CR28]; Ramos et al. [@CR42]). Furthermore, it is interesting that decreased expression of *focA* that is responsible for F1C fimbriae synthesis in *Ec*N only appeared in case of the simultaneous knockdown expression of *ccdAB* and *hipAB* (Fig. [6a](#Fig6){ref-type="fig"}). F1C fimbriae has been shown to be indispensable in the biofilm formation of *E. coli* wherein *focA* mutant is defective in biofilm building (Lasaro et al. [@CR29]). Thus, we propose that the contribution of F1C fimbriae to the biofilm formation of *Ec*N is mediated by CcdAB and HipAB on multiple levels. Overall, the mechanisms involved in the biofilm formation of *Ec*N are complicated; CcdAB and HipAB are suggested to achieve a collectively positive regulating role at least (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Model of identified HipAB and CcdAB-mediated genes in *Ec*N. Transcriptional silencing of *hipAB* by CRISPRi inhibits the expression of a gene involved in DNA replication (*gyrA*) and upregulates the expression of genes involved in stringent response (*rpoS* and *relA*), SOS response (*recA* and *lexA*), and RNA interaction (*hfq*); transcriptional silencing of *ccdAB* by CRISPRi inhibits *lexA* expression and upregulates the expression of *gyrA*, *rpoS*, *relA*, *recA*, and *hfq*. These changes eventually lead to the reduced biofilm formation and persister formation upon gentamycin treatment in *Ec*N

Studies of bacterial persistence in *E. coli* have been widely performed, of which toxin-antitoxin systems are generally accepted to be the regulators of persistence (Page and Peti [@CR38]; Semanjski et al. [@CR48]). However, these findings have recently been challenged (Goormaghtigh et al. [@CR16]). Nevertheless, we suggest here that the persister formation of *Ec*N in the stationary phase is mediated by CcdAB and HipAB. On the other hand, it was interesting to find that knockdown expression of *hipAB* induced upregulation of *rpoS* and *relA* expression, which was usually observed in case of HipA overexpression (Durfee et al. [@CR11]; Kaspy et al. [@CR24]). This may be explained that the stringent response is simultaneously controlled by other mechanisms while the silence of *hipAB* expression seems to promote this process. Besides, we found that the transcriptional halt of *hipAB* induced SOS response (Fig. [6b](#Fig6){ref-type="fig"}). The direct link between HipAB and SOS response is rarely reported in *E. coli*, whereas our results suggest that persister formation mediated by HipAB may have an indirect correlation with SOS response in *Ec*N (Fig. [7](#Fig7){ref-type="fig"}). CcdB inhibits DNA replication by binding to gyrase-DNA complex and blocking the DNA polymerase passage, leading to DNA double-strand breaks and cell growth inhibition (Bahassi et al. [@CR3]). Thus, it is possible that the repressed expression of *ccdB* will promote DNA replication. This case was found in *Ec*N where knockdown expression of *ccdAB* resulted in the upregulation of *gyrA* expression. Moreover, it was surprising to find the upregulation of *recA* expression in Δ*ccdAB* mutant since this generally happens upon *ccdB* overexpression (Tripathi et al. [@CR55]). This could not be ascribed to the experimental bias since the survival of *the* Δ*ccdAB* mutant was significantly increased during exposure to norfloxacin (Fig. [6b](#Fig6){ref-type="fig"}), indicating that expression of *recA* is regulated by other unknown mechanisms. Thus, a future study aiming to explore the molecular mechanisms underlying intrinsic correlation between TASs (e.g., CcdAB), SOS response, and persister formation will enhance our understanding of the persistence phenomenon in *Ec*N.

Toxin-antitoxin systems, the potential regulator in *Ec*N for bacterial interference? {#Sec20}
-------------------------------------------------------------------------------------

The use of antimicrobial compounds in the treatment of bowel disorders caused by the infection of pathogenic *E. coli* and other fatal bacteria is controversial because of the emergence of antibiotic resistance (persistence) as well as observed increased endotoxin release after antibiotic exposure in some enteropathogen (Bielaszewska et al. [@CR6]; Mohsin et al. [@CR34]). In past decades, the probiotic *Ec*N has been widely used in the treatment of intestinal disorders such as ulcerative colitis, Crohn's disease, and inflammatory bowel disease due to its high ability in competing with enteropathogen (Chen et al. [@CR9]; Huebner et al. [@CR22]; Rembacken et al. [@CR44])*. Ec*N has been reported to have a better capacity in biofilm formation and help to outcompete the most known pathogenic *E. coli* (Hancock et al. [@CR18]). However, in addition to the finding that F1C fimbriae are necessary for the biofilm formation of *Ec*N, largely unknown factors involved in the regulation of biofilm formation are waiting for elucidation (Lasaro et al. [@CR29]). Besides, whether the formation of persister cells helps *Ec*N combat with other bacteria and survive under hostile environments in the intestine remains elusive. The results obtained in this study shed some light on this field. Thus, to prompt the application of *Ec*N in bacterial interference, a future study focusing on the elucidation of the correlation between TASs, robust biofilm, and persister formation of *Ec*N during intestine colonization will be helpful.

CRISPRi is proposed to be an efficient tool in annotating toxin-antitoxin systems in situ {#Sec21}
-----------------------------------------------------------------------------------------

A common difficulty encountered during the study of specific TAS is functional redundancy with other TASs as well as the number duplicates (Ramage et al. [@CR40]). Deletion and restoration of gene expression are the methods that have been usually adopted to annotate the function of a given gene. In contrast to one gene, sometimes, multiple TASs needed to be knocked out before there is an observable phenotype, which asks for a long period for molecular manipulation (Kim et al. [@CR25]; Kolodkin-Gal et al. [@CR27]). In this case, an efficient and convenient molecular tool is of great importance. Currently, the CRISPR interference (CRISPRi) system has been widely employed in the regulation of gene expression (Kim et al. [@CR26]; Qi et al. [@CR39]; Wang et al. [@CR59]). However, to the best of our knowledge, it is the first time that the CRISPRi tool is applied in the functional annotation of type II TASs. To inhibit the expression of either *ccdB* or *hipA*, we designed three N20 sequences for each gene. The results showed that each of them was functional but with different efficiency (data not shown). By choosing the best N20 sequences, two chromosomal TASs *ccdAB* and *hipAB* in *Ec*N were annotated smoothly, suggesting that CRISPRi could be a strong candidate tool in TAS study among *E. coli* as well as other bacteria. On the other hand, CRISPRi is capable of producing different levels of the expression of a targeted gene either by knocking down or activating, thus helping to study the behavioral changes of cells upon various conditions (Tao et al. [@CR54]). This makes sense when we consider the clinical application of *Ec*N where cell viability is one important factor that determines the therapeutic process. In general, we could enhance the oral delivery to guarantee the therapeutic effect. Our findings suggest that sustaining the cell viability of *Ec*N dynamically under the intestine environment by regulating the expression of TAS is preferable and constructive. In addition, genetic engineering of the *Ec*N chromosome usually happens for *Ec*N-based vaccine development, in which the increased or decreased gene expression of interest is necessary (Chaudhari et al. [@CR7]; Ou et al. [@CR37]). In this case, CRISPRi would be a robust tool for the regulation of gene expression in *Ec*N.

In conclusion, we reasoned that the *ECOLIN_00240-ECOLIN_0024*5 and *ECOLIN_08365-ECOLIN_08370* operon of *Ec*N encoded CcdAB and HipAB, respectively. By CRISPRi, *ccdAB* and *hipAB* were shown to be involved in the formation of biofilm and persister cells in *Ec*N. Moreover, we evidenced that biofilm formation and cell persistence regulated by CcdAB and HipAB were associated with the SOS and stringent response in *Ec*N (Fig. [7](#Fig7){ref-type="fig"}), which may be helpful for the future study of the intestinal colonization of *Ec*N. Furthermore, the CRISPRi approach is proposed to be an efficient and precise tool in deciphering multiple TASs.
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